Press Releases

SAN DIEGO--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of therapies to treat drug-resistant infections using bacteriophage-based technology, announces that CEO Dr. Paul Grint will present a company overview on June 21, 2017, at 2:15 p.m. Pacific time at the 2017 BIO International Convention. Dr. Grint will also participate in the panel session, “Adding Tools to the Toolbox: New Technologies to Overcome AMR Mechanisms,” on the same day beginning at 4:15 p.m. Pacific time. The 2017 BIO International Convention is being held June 19-22 in San Diego.

“BIO is an excellent opportunity to showcase our phage-based technology and its ability to combat multidrug-resistant (MDR) infections to industry representatives and investors from around the world,” said Dr. Grint. “We are actively seeking partners to advance our clinical program in chronic rhinosinusitis (CRS) and preclinical program in cystic fibrosis, while we also focus on developing personalized, precision phage therapies for patients who suffer from serious or life-threatening MDR bacterial infections.”

AmpliPhi’s management team will be available for one-on-one meetings with business development representatives and investment professionals attending the BIO International Convention. Those interested in meeting with AmpliPhi are encouraged to use the scheduling platform available through the conference website hosted by the Biotechnology Innovation Organization at http://convention.bio.org/partner/.

More information about the BIO International Convention is available at https://convention.bio.org/.

About AmpliPhi Biosciences

AmpliPhi Biosciences Corporation is a biotechnology company pioneering the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. In May 2017, AmpliPhi announced an additional near-term strategic emphasis on developing precisely targeted and personalized bacteriophage therapies for patients with serious or life-threatening antibiotic-resistant infections. AmpliPhi has reported results from two Phase 1 clinical trials of AB-SA01, one for the treatment of Staphylococcus aureus in CRS patients (safety and preliminary efficacy) and one to evaluate the safety of AB-SA01 when administered topically to the intact skin of healthy adults.

In May 2017, AmpliPhi announced the completion of an underwritten public offering of common stock and common warrants resulting in net proceeds to AmpliPhi of approximately $9.1 million.

More information is available at www.ampliphibio.com.